Regenxbio Inc at Barclays Gene Editing & Gene Therapy Summit (Virtual) Transcript
Good afternoon, everyone. My name is Gena Wang. I'm SMID-cap biotech analyst at Barclays. Welcome to our fifth Gene Editing and Gene Therapy Summit. It is my great pleasure to introduce our next speaker, Ken Mills, Chief Executive Officer from REGENXBIO. Ken, I will hand over to you.
Gena, thanks very much, and thanks to you and the Barclays team for inviting us to this event. We always enjoy spending time talking about REGENXBIO and things happening in the field. And a few slides that I'm going to bring up here to give a quick overview, and then I know we'll transition into a discussion-based format. I'll get my technology working.
Thanks. Before I get into the background, I just want to acknowledge the forward-looking statement disclaimer here on the second slide that there may be some discussion of factors that relate to forward-looking statements on my part during this quick talk and discussion.
REGENXBIO
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
